{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:34:37Z","timestamp":1774017277568,"version":"3.50.1"},"reference-count":14,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ViiV Healthcare"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In GEMINI-1\/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC) in achieving viral suppression (viral load [VL] &lt; 50 copies\/mL) in treatment-naive adults. Abbott\u2019s RealTime HIV-1 assay provides quantitative VL (40\u201310,000,000 copies\/mL) and qualitative target detected or target not detected (TND) for VL &lt; 40 copies\/mL. This post hoc analysis assessed very-low-level viremia and \u201cblips\u201d through Week 144. Proportions with VL &lt; 40 copies\/mL and TND are presented overall and by baseline VL and CD4+ cell count. \u201cBlips\u201d (single VL \u2265 50 to &lt;200 copies\/mL with adjacent values &lt; 50 copies\/mL) were assessed from Day 1 after VL suppression and from Weeks 48 through to 144. Proportions with TND increased through Week 48 and were similar between groups at all visits (Week 144: dolutegravir + lamivudine, 451\/716 [63%]; dolutegravir + TDF\/FTC, 465\/717 [65%]). By observed analysis, TND rates were similar between groups across baseline subgroups. Through Week 144, proportions with \u22651 \u201cblip\u201d were generally comparable for dolutegravir + lamivudine vs. dolutegravir + TDF\/FTC from Day 1 (15% vs. 20%) and from Week 48 (7% vs. 11%). Through 144 weeks, the proportions with TND or \u201cblips\u201d were similar between dolutegravir + lamivudine and the three-drug comparator, reinforcing the efficacy and durability of dolutegravir + lamivudine.<\/jats:p>","DOI":"10.3390\/v16030405","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T04:03:50Z","timestamp":1709697830000},"page":"405","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate\/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6803-2346","authenticated-orcid":false,"given":"Mark","family":"Underwood","sequence":"first","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimgaile","family":"Urbaityte","sequence":"additional","affiliation":[{"name":"GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruolan","family":"Wang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Horton","sequence":"additional","affiliation":[{"name":"Parexel, 2520 Meridian Parkway, Durham, NC 27713, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Oyee","sequence":"additional","affiliation":[{"name":"GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dainielle","family":"Fox","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9296-367X","authenticated-orcid":false,"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choy","family":"Man","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Sievers","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.18683\/germs.2017.1115","article-title":"2-Drug regimens in HIV treatment: Pharmacological considerations","volume":"7","author":"Back","year":"2017","journal-title":"Germs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1016\/S2352-3018(22)00249-1","article-title":"Two-drug regimens for HIV treatment","volume":"9","author":"Gibas","year":"2022","journal-title":"Lancet HIV"},{"key":"ref_3","unstructured":"(2023). Dovato [Prescribing Information], ViiV Healthcare."},{"key":"ref_4","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2023, July 23). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"ref_5","unstructured":"European AIDS Clinical Society (2023, October 18). Guidelines Version 12.0. Available online: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy","volume":"106","author":"Dinoso","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/AAC.00076-14","article-title":"Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients","volume":"58","author":"Ryscavage","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","unstructured":"(2011). Abbott RealTime HIV-1 Assay [Package Insert], Abbott Molecular Inc."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lau, C.Y., Adan, M.A., and Maldarelli, F. (2021). Why the HIV reservoir never runs dry: Clonal expansion and the characteristics of HIV-infected cells challenge strategies to cure and control HIV infection. Viruses, 13.","DOI":"10.3390\/v13122512"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkl092","article-title":"HIV-1 viral load blips are of limited clinical significance","volume":"57","author":"Lee","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1093\/cid\/ciz937","article-title":"What\u2019s all this fuss I hear about viral \u201cblips\u201d?","volume":"70","author":"Saag","year":"2020","journal-title":"Clin. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/405\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:50Z","timestamp":1760105390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["v16030405"],"URL":"https:\/\/doi.org\/10.3390\/v16030405","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}